Ever since the COVID-19 vaccines were authorized for emergency use, researchers have been tracking the risk of myocarditis and pericarditis — another heart inflammation condition that affects the outer lining of the heart but has similar symptoms, such as chest pain, shortness of breath and a pounding heartbeat, according to the CDC.
In a recent study, Canadian researchers found that heart inflammation cases were two- to threefold higher after Moderna’s vaccine compared to Pfizer’s. The study concluded that the risk is still low, but multiple vaccine-makers will test their formulas for long-term health effects of myocarditis after COVID-19 vaccination, according to the CDC. The yearslong trials are set to begin in a few months.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
